The true potential of ALK inhibitors in NB will be determined over the next few years after completion of current clinical studies, though it is anticipated that long-term use of these compounds will require combinatorial targeting of pathways downstream of ALK, functionally-related ‘bypass’ mechanisms and concomitant oncogenic pathways. Here, ALK is linked to neuroblastoma.